Demian Pardo

Demian Pardo

Auto-generated profile, based on publicly available information

Demian Pardo

Madrid Institute for Advanced Studies in Nanoscience (IMDEA Nanociencia), 28049, Madrid, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2022 in Analytica Chimica Acta
Verified
Journal Article
Open access
MLMaría López-Valls
María López-Valls
CECarmen Escalona-Noguero
Carmen Escalona-Noguero
CRCiro Rodríguez-Díaz
Ciro Rodríguez-Díaz
DPDemian Pardo
Demian Pardo
CMCastellanos Molina Milagros
Castellanos Molina Milagros
BSBegoña Sot
Begoña Sot
The COVID-19 pandemic has brought to light the need for fast and sensitive detection methods to prevent the spread of pathogens. The scientific community is making a great effort to design new molecular detection methods suitable for fast point-of-care applications. In this regard, a variety of approaches have been developed or optimized, including isothermal amplification of viral nucleic acids, CRISPR-mediated target recognition, and read-out systems based on nanomaterials.

16 March 2022 in Talanta
Verified
Journal Article
Open access
CRCiro Rodríguez
Ciro Rodríguez
NLNuria Lafuente-Gómez
Nuria Lafuente-Gómez
CCCatarina Coutinho
Catarina Coutinho
DPDemián Pardo
Demián Pardo
HAHernán Alarcón-Iniesta
Hernán Alarcón-Iniesta
Álvaro SomozaÁlvaro Somoza
Álvaro Somoza
We present a fast, reliable and easy to scale-up colorimetric sensor based on gold nanoparticles (AuNPs) to detect the sequences coding for the RdRp, E, and S proteins of SARS-CoV-2. The optimization of the system (so-called “the sensor”) includes the evaluation of different sizes of nanoparticles, sequences of oligonucleotides and buffers. It is stable for months without any noticeable decrease in its activity, allowing the detection of SARS-CoV-2 sequences by the naked eye in 15 min. The efficiency and selectivity of detection, in terms of significative colorimetric changes in the solution upon target recognition, are qualitatively (visually) and quantitatively (absorbance measurements) assessed using synthetic samples and samples derived from infected cells and patients. Furthermore, an easy and affordable amplification approach is implemented to increase the system's sensitivity for detecting high and medium viral loads (≥103 - 104 viral RNA copies/μl) in patient samples. The whole process (amplification and detection) takes 2.5 h. Due to the ease of use, stability and minimum equipment requirements, the proposed approach can be a valuable tool for the detection of SARS-CoV-2 at facilities with limited resources.

10 November 2026 in Lab on a Chip
Verified
Journal Article
Closed access
AMAlberto Martín-Asensio
Alberto Martín-Asensio
IPIrene Pardo
Irene Pardo
LPLucía Pardinas
Lucía Pardinas
EVEdgar Eduardo Villalobos-Portillo
Edgar Eduardo Villalobos-Portillo
DPDemian Pardo
Demian Pardo
IRIsabel Rodríguez
Isabel Rodríguez
Label-free X-ray fluorescence imaging tracks nanomedicine diffusion in biological matrices within 3D-printed microfluidic devices.

19 November 2026 in bioRxiv
Verified
Preprint
Open access
DCDiego Castaño-Esteban
Diego Castaño-Esteban
MLMaría López-Valls
María López-Valls
MSMirentxu Santos
Mirentxu Santos
EREnrique Recuero
Enrique Recuero
LMLydia Martín-Vallejo
Lydia Martín-Vallejo
BSBegoña Sot
Begoña Sot
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, largely due to its poor response to chemotherapy and the development of drug resistance. Survivin (BIRC5), an inhibitor of apoptosis frequently overexpressed in PDAC, contributes to tumor cell survival and gemcitabine resistance, making it an attractive therapeutic target. Here, we developed a lipid nanoparticle (LNP)-based platform for the delivery of preassembled spCas13b ribonucleoproteins (RNPs) to achieve transient and sequence-specific RNA silencing in pancreatic cancer cells. We optimized ionizable lipid formulations for Cas13b RNP encapsulation and identified a formulation achieving approximately 80% encapsulation efficiency, with sustained colloidal stability and gene-silencing activity during seven days of storage at 4°C. LNP-delivered Cas13b RNPs efficiently silenced endogenous BIRC5 in three pancreatic cancer cell lines, reducing survivin protein levels and inducing apoptosis. In gemcitabine-resistant PANC-1 cells, BIRC5 silencing synergistically enhanced the cytotoxic effect of gemcitabine in vitro. This therapeutic combination was further evaluated in a PANC-1 xenograft model, where only the combined administration of BIRC5-targeting Cas13b RNP-LNPs and gemcitabine significantly inhibited tumor growth, without apparent systemic toxicity. Intratumoral administration also restricted nanoparticle distribution to the injected tumors. These findings establish LNP-mediated delivery of Cas13b RNPs as a new strategy for transient RNA-targeted therapy and provide proof of concept for combining survivin silencing by Cas13b with chemotherapy to address gemcitabine resistance in pancreatic cancer.